EMERYVILLE, Calif., June 22, 2022 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced its participation in the 27e Annual European Society for Animal Cell Technology (ESCAT), to be held June 26-29, 2022 at the Lisbon Congress Center in Lisbon, Portugal. This year’s conference, whose motto is “Advanced Cellular Technologies: Making Protein, Cellular and Gene Therapies a Reality”, is designed to provide scientists, engineers and other specialists with access to the latest innovations, advances, tools and equipment in cellular technology.
At ESCAT, Berkeley Lights will participate in a symposium session focused on accelerating cell line engineering and development. The company will also be showcasing its Beacon platform technology and workflows in booth #39 for attendees to explore with hands-on demonstrations of our optofluidic technology as well as how to apply the Berkeley Lights Custom Productivity Test. to rapidly select clones that produce high quality bispecific molecules.
Symposium session: Advance and automate cell profiling with Berkeley Lights technology and tools to accelerate cell line engineering and development
Date: Sunday June 26, 10:30 a.m. – 12:00 p.m. (GMT+1), Auditorium VIII
Abstract: The generation of stable CHO cell lines for the manufacture of biologics is a resource-intensive process that can add months to therapeutic or reagent development times. During this session of the ESCAT Symposium, attendees will learn how the Beacon Platform removes critical bottlenecks and provides valuable insights into function and quality much earlier in the process by showcasing the work of Rennos Fragkoudis, director of the Edinburgh Genome Foundry (EGF) at the university. from Edinburgh.
Fragkoudis will present how EGF’s suite of advanced computing tools and integrated automation technologies have facilitated projects in gene therapy, vaccine development and metabolic engineering. As the first of its kind at a European academic institution, EGF’s investment in the Beacon platform has provided its customers with unparalleled access to state-of-the-art technology to perform previously unexploitable high-throughput single-cell screening experiments.
In addition, Peter O’Callaghan, Head of Expression Systems Science at Lonza, will present insights into how Lonza is harnessing new cell and process technologies to improve cell line constructs, through the use of its multiple Beacon platforms.
Finally, a panel discussion, moderated by Berkeley Lights, will conclude this session of the symposium which will focus on the role of advanced screening technologies, automation and computational tools in accelerating engineering and lineage development projects. cell phones in universities and industry.
About Berkeley Lights
Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights platform captures in-depth phenotypic, functional and genotypic information for thousands of individual cells in parallel and can also deliver the live biology customers want in the form of the best cells. Our platform is a fully integrated, end-to-end solution, featuring proprietary consumables including our OptoSelect® chips and reagent kits, advanced automation systems and application software. We have developed the Berkeley Lights platform to provide the most advanced environment for the rapid functional characterization of large-scale single cells, which aims to set an industry standard for our customers throughout their supply chain. value of cell-based products.
To the extent that the statements in this press release are not descriptions of historical facts regarding Berkeley Lights or its products, they are forward-looking statements reflecting management’s current beliefs and expectations. These forward-looking statements involve substantial known and unknown risks and uncertainties relating to future events, and actual results and product performance could differ materially from those expressed or implied by the forward-looking statements. Berkeley Lights assumes no obligation to update or revise any forward-looking statements. For a more detailed description of the risks and uncertainties associated with the growth and continued development of the Company, see the statements in the “Risk Factors” sections, and elsewhere, in our filings with the Securities and Exchange Commission. United States.